breast-cancer-and-cancer-science-2019-keynote

2 / 3

Page 9
September 16-17, 2019 | Edinburgh, Scotland
Volume 3 Breast Cancer 2019 & Cancer Science 2019
September 16-17, 2019
Journal of Cancer & Metastasis Research
BREAST CANCER
CANCER SCIENCE AND THERAPY
2nd World Congress on
&
J Can Res Metastasis, Volume 3
Five day Accelerated Partial Breast Irradiation (APBI) using Stereotactic Body
Irradiation Therapy (SBRT) in stage 0-II breast cancer: A preliminary report of 69
cases
Background: Randomized trials in Stage 0-II breast cancer with 10 year follow-up have proven that Accelerated Partial Breast
Irradiation (APBI) given via radiation implant in 5 days is equivalent to Whole Breast Radiation Therapy (WBRT) in 6 weeks
in regard to tumor local recurrence (LR). However, implants are invasive and complications, including infection and soft tissue
necrosis requiring possible mastectomy have been significant. RecentlyAPBI using non-invasive IntensityModulated Radiation
Therapy (IMRT) in 5 days was shown to be equivalent to WBRT in 6 weeks with 5 year follow-up, with respect to LR. APBI
IMRT was superior in regard to side effects, and cosmesis.
Objectives: In the randomized clinical trial of APBI IMRT, the Clinical Target Volume (CTV) was defined by the injection of
individual fiducial markers bordering the surgical cavity. We have used the simpler less labor intensive Biozorb fiducial system
to localize the CTV for SBRT.
Materials and Methods: Between 2017 and 2019, 69 patients underwent SBRT targeted to Biozorb defined CTV. Eligible
patients were older than age 40, had tumor sizes < 3 cm, negative surgical margins, and negative node dissections. SBRT dose
was 30 Gy given in 5 fractions. The Planning Target Volume (PTV) ranged from 27 to 355 cc with a median of 80 cc. PTV =
CTV + 1-2 cm.
Results: Follow-up ranged from 1-18 months with a median of 9 months. LR has been 0% (0/69). There were no skin reactions.
Cosmetic results were rated excellent in 100% (69/69) of cases.
Conclusions: Non-invasive APBI with SBRT given over 5 days targeted to Biozorb has resulted in LR, complications, and
cosmetic results which compare favorably to invasive APBI given via implant. At last follow-up, there have been no LR, skin
reactions, or complications. Cosmesis has been excellent in 100% of patients.
Biography
Rufus Mark graduated from Yale University with Phi Beta Kappa and Summa Cum Laude honors. He went on to graduate from UCLA
Medical School and then Residency in Radiation Oncology also at UCLA. He has extensive clinical experience in: High Dose Rate (HDR)
Radiation Implants of the Prostate, Breast, Cervix, and Lung; Stereotactic Body Radiation Therapy (SBRT) of the Lung, Prostate, Breast and
Liver; Stereotactic Radiosurgery (SRS) for Trigeminal Neuralgia, Parkinson’s Disease, and multiple brain tumors; and Intensity Modulated
Radiation Therapy (IMRT) of all sites. He has made more than 250 presentations of papers/abstracts at peer reviewed meetings including
ASTRO, ESTRO, ACRO, ARS, ABS, and RSNA. He was unanimously voted the best lecturer and clinical instructor by the Baylor Scott
and White Residents in 2017-2018. He is currently Medical Director of Radiation Oncology at the Baylor Scott and White Medical Center in
Waxahachie TX.
Rufus Mark
Baylor Scott and White Medical Center, USA